Copyright
©The Author(s) 2017.
World J Biol Chem. May 26, 2017; 8(2): 102-107
Published online May 26, 2017. doi: 10.4331/wjbc.v8.i2.102
Published online May 26, 2017. doi: 10.4331/wjbc.v8.i2.102
Name | Type ofinhibitor | Preclinical/clinical trails |
Fumagillin[7-10] | Irreversible | N/A |
TNP-470[12,13] | Irreversible | Phase I |
PPI-2458[49] | Irreversible | Phase I |
CKD-732[61-64] (ZGN-433, beloranib) | Irreversible | Phase II/III |
SDX-7320[59,60] | Irreversible | Phase II |
Bengamides[65] (LAF389) | Reversible | Phase I |
2-Hydroxy-3-aminoamides[66] | Reversible | Preclinical |
Anthranilic acid sulfonamides[67] | Reversible | Preclinical |
Triazoles[68] | Reversible | Preclinical |
Indazoles[69] | Reversible | Preclinical |
Pyrazolo[4,3-b]indoles[70] | Reversible | Preclinical |
- Citation: Chang YH. Common therapeutic target for both cancer and obesity. World J Biol Chem 2017; 8(2): 102-107
- URL: https://www.wjgnet.com/1949-8454/full/v8/i2/102.htm
- DOI: https://dx.doi.org/10.4331/wjbc.v8.i2.102